Canzon to explore German market by partnering with Lykos Verde

By Nikita Chaurasia  Date: 2020-07-06

Canzon to explore German market by partnering with Lykos Verde

Canzon, an Israeli enterprise selling CBD-based products in Europe has reportedly entered a partnership worth NIS 6 million yearly with German distribution firm Lykos Verde.

Sources close to the matter stated that as per the agreement, Lykos Verde will acquire exclusive rights for distributing Canzon brand at over 3,000 sports stores & fitness clubs, 1,000 organic food stores, and 3,000 pharmacies in Germany.

The deal was finalized through mediation by Yuval Soiref, owner of PharmaCann International, which is an external consultant to Canzon Europe, sources claimed.

Alon Carmeli, Canzon founder was reported saying that the partnership will enable the firm to acquire a dominant spot among physical stores across Germany, thereby allowing it to become a frontrunner in the ever-growing CBD sector.

Anna-Sophia Kouparanis, Managing Director of Lykos Verde stated that the company is enthralled with the quality as well as the innovative design of the products Canzon offers. She added that the Israeli company will provide a novel solution in the German market and is looking forward to working together in the upcoming years. 

For those uninitiated, Canzon is a leading manufacturer of various types of CBD-based products which do not need a medical prescription. The company evidently possesses around 24 products in eight categories for both paramedical as well as cosmetic use. It produces products such as snack bars for curing joint problems among dogs, day & night anti-aging creams as well as products for treating psoriasis and acne.

On the other hand, Lykos Verde is a pharmaceutical wholesaler that operates out of Frankfurt, Germany. According to industry experts, the company is currently focusing on global expansion by deploying an international distribution network. It is also concentrating on increasing pharmaceutical sales among pharmacists and doctors as well as other personnel in the industry.

Source Credits –

https://en.globes.co.il/en/article-canzon-signs-cannabis-cbd-german-distribution-deal-1001334661

https://www.canzon.com/about-us/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...